XTL Advances Pain Drug to Phase IIb
Posted on: Monday, 10 September 2007, 12:00 CDT
XTL Biopharmaceuticals has started a Phase IIb clinical trial of bicifadine, a serotonin and norepinephrine reuptake inhibitor for the treatment of diabetic neuropathic pain.
The Phase IIb study is a randomized, double-blind, placebo-controlled study comparing 200mg 3x/day and 400mg 3x/day of bicifadine versus placebo, with a 1:1:1 randomization between the three arms, in patients with diabetic neuropathic pain. The trial is designed to enroll approximately 330 patients. Approximately 45 clinical centers in the US, Europe and India will participate in the study.
The primary endpoint of the study is to compare the efficacy of each of the two active doses of bicifadine (200mg and 400mg) versus placebo in reduction of pain associated with diabetic neuropathy, at baseline (at the time of randomization) versus week 14 (week 12 of the steady-state phase). Pain will be measured based on a 24-hour pain rating using the 11-point pain intensity numeric rating scale (formerly referred to as the LIKERT scale).
Bicifadine is being developed for the treatment of diabetic neuropathic pain which represents a significant unmet medical need in the rapidly growing multi-billion dollar neuropathic pain market, according to XTL. Bicifadine is a member of the SNRI drug class, a proven class in the treatment of diabetic neuropathic pain. XTL in-licensed the world-wide rights to bicifadine from Dov Pharmaceutical in January 2007.
Source: Datamonitor
Related Articles
- Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
- Doctors Often Use Placebo Treatments For Patients
- Death Risk Halts Diabetes Study
- One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
- IBC Expands Coverage of Case Studies and Projects in Preclinical, Phase 1 and Phase 2
- Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
- Diabetes Study Called Partial Success
- Pain Therapeutics Terminates Drug Candidate for the Treatment of Irritable Bowel Syndrome
- The CARDS Investigators: Primary Prevention of Cardiovascular Disease With Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo- Controlled Trial
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds